Intra-Cellular Therapies (ITCI) Stock Rating Reaffirmed by Cantor Fitzgerald

Share on StockTwits

Cantor Fitzgerald reaffirmed their overweight rating on shares of Intra-Cellular Therapies (NASDAQ:ITCI) in a research report report published on Thursday, The Fly reports. Cantor Fitzgerald currently has a $29.00 price objective on the biopharmaceutical company’s stock, up from their prior price objective of $26.00.

A number of other analysts also recently weighed in on ITCI. ValuEngine downgraded Intra-Cellular Therapies from a hold rating to a sell rating in a report on Thursday, January 24th. BidaskClub upgraded Intra-Cellular Therapies from a strong sell rating to a sell rating in a report on Saturday, February 2nd. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the stock. The company presently has an average rating of Hold and an average target price of $27.60.

Shares of NASDAQ:ITCI opened at $13.47 on Thursday. The firm has a market cap of $742.43 million, a P/E ratio of -4.74 and a beta of 1.39. The company has a debt-to-equity ratio of 0.07, a current ratio of 9.59 and a quick ratio of 9.59. Intra-Cellular Therapies has a 12-month low of $10.21 and a 12-month high of $23.64.

Intra-Cellular Therapies (NASDAQ:ITCI) last announced its earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.90) by $0.27. Analysts expect that Intra-Cellular Therapies will post -3.71 earnings per share for the current fiscal year.

In other Intra-Cellular Therapies news, Director Christopher D. Alafi purchased 100,000 shares of the firm’s stock in a transaction on Tuesday, May 14th. The stock was purchased at an average cost of $12.56 per share, for a total transaction of $1,256,000.00. Following the acquisition, the director now owns 750,106 shares in the company, valued at approximately $9,421,331.36. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 17.40% of the company’s stock.

A number of institutional investors have recently modified their holdings of the business. FMR LLC grew its holdings in Intra-Cellular Therapies by 0.7% during the 1st quarter. FMR LLC now owns 8,267,510 shares of the biopharmaceutical company’s stock worth $100,698,000 after acquiring an additional 58,561 shares during the period. BlueMountain Capital Management LLC grew its stake in shares of Intra-Cellular Therapies by 100.0% in the 1st quarter. BlueMountain Capital Management LLC now owns 40,330 shares of the biopharmaceutical company’s stock valued at $491,000 after buying an additional 20,161 shares during the period. Man Group plc grew its stake in shares of Intra-Cellular Therapies by 21.6% in the 1st quarter. Man Group plc now owns 243,003 shares of the biopharmaceutical company’s stock valued at $2,960,000 after buying an additional 43,200 shares during the period. Geode Capital Management LLC grew its stake in shares of Intra-Cellular Therapies by 16.8% in the 1st quarter. Geode Capital Management LLC now owns 612,614 shares of the biopharmaceutical company’s stock valued at $7,461,000 after buying an additional 88,153 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its stake in shares of Intra-Cellular Therapies by 4.8% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 267,340 shares of the biopharmaceutical company’s stock valued at $3,257,000 after buying an additional 12,289 shares during the period. Hedge funds and other institutional investors own 71.11% of the company’s stock.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative disorders. The company is developing its lead drug candidate, lumateperone for the treatment of schizophrenia, bipolar disorder, behavioral disturbances associated with dementia, autism, and other CNS diseases.

Featured Article: Why is the ROA ratio important?

The Fly

Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Goldman Sachs BDC Inc  Receives Average Recommendation of “Hold” from Brokerages
Goldman Sachs BDC Inc Receives Average Recommendation of “Hold” from Brokerages
Analysts Set Daily Mail and General Trust P L C  Price Target at $685.57
Analysts Set Daily Mail and General Trust P L C Price Target at $685.57
Novocure Ltd  Receives $52.00 Consensus Target Price from Brokerages
Novocure Ltd Receives $52.00 Consensus Target Price from Brokerages
PetIQ Inc  Given Average Rating of “Buy” by Analysts
PetIQ Inc Given Average Rating of “Buy” by Analysts
Banco Santander SA  Receives Average Recommendation of “Buy” from Brokerages
Banco Santander SA Receives Average Recommendation of “Buy” from Brokerages
Precision Drilling Corp  Receives Average Recommendation of “Buy” from Analysts
Precision Drilling Corp Receives Average Recommendation of “Buy” from Analysts


 
© 2006-2019 Zolmax.